Abstract
Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74 - 0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71 - 0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
Keywords: Drug design, factor Xa, QSAR, Neural Networks, thrombin.
Current Computer-Aided Drug Design
Title:Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks
Volume: 10 Issue: 3
Author(s): Vasyl Kovalishyn, Vsevolod Tanchuk, Iryna Kopernyk, Volodymyr Prokopenko and Larysa Metelytsia
Affiliation:
Keywords: Drug design, factor Xa, QSAR, Neural Networks, thrombin.
Abstract: Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74 - 0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71 - 0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
Export Options
About this article
Cite this article as:
Kovalishyn Vasyl, Tanchuk Vsevolod, Kopernyk Iryna, Prokopenko Volodymyr and Metelytsia Larysa, Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks, Current Computer-Aided Drug Design 2014; 10 (3) . https://dx.doi.org/10.2174/157340991003150302231419
DOI https://dx.doi.org/10.2174/157340991003150302231419 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Extraction of Triacylglycerols and Fatty Acids Using Supercritical Fluids - Review
Current Analytical Chemistry Fibrinolytic Factors in Liver Fibrosis
Current Pharmaceutical Biotechnology The Effects of Hemocoagulase on Coagulation Factors in an Elderly Patient with Upper Gastrointestinal Hemorrhage: A Case Report
Current Drug Safety Subject Index to Volume 4
Current Drug Targets - Cardiovascular & Hematological Disorders Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Fishing Anti-Inflammatories from Known Drugs: In Silico Repurposing, Design, Synthesis and Biological Evaluation of Bisacodyl Analogues
Current Topics in Medicinal Chemistry Severe Preeclampsia
Current Women`s Health Reviews The Pivotal Role of Nitric Oxide: Effects on the Nervous and Immune Systems
Current Pharmaceutical Design Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets Isolation and Characterization of CD39-like Phosphodiesterase (Cc-PDE) from <i>Cerastes cerastes</i> Venom: Molecular Inhibitory Mechanism of Antiaggregation and Anticoagulation
Protein & Peptide Letters Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
CNS & Neurological Disorders - Drug Targets A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Biosafety of Adenoviral Vectors
Current Gene Therapy Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Antiplatelet and Anticoagulation Treatment in Patients with Thrombocytopenia
Current Pharmaceutical Design Remote Ischemic Conditioning Improves Cognitive Function During Cerebral Vascular Injury Through the Induction of Autophagy
Current Neurovascular Research Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design